New schizophrenia drug MK-8189 passes early safety check in small study

NCT ID NCT04506905

First seen Apr 29, 2026 · Last updated May 05, 2026 · Updated 2 times

Summary

This early-phase study tested the safety and tolerability of a new drug called MK-8189 (elpipodect) in 63 adults with schizophrenia, including both younger and elderly participants. The goal was to find safe dosing schedules and see how the drug moves through the body. No claims about effectiveness were made; the focus was purely on safety and tolerability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Collaborative NeuroScience Network ( Site 0008)

    Long Beach, California, 90806, United States

  • Hassman Research Institute ( Site 0007)

    Berlin, New Jersey, 08009, United States

  • Parexel ( Site 0004)

    Glendale, California, 91206, United States

  • RCA at Fort Lauderdale Behavioral Health Center ( Site 0006)

    Oakland Park, Florida, 33334, United States

  • Velocity Clinical Research, Hallandale Beach ( Site 0001)

    Hallandale, Florida, 33009, United States

  • Woodland Research Northwest, LLC ( Site 0002)

    Rogers, Arkansas, 72758-6442, United States

Conditions

Explore the condition pages connected to this study.